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The evolutionary progression from primary to metastatic prostate cancer is largely uncharted,
and the implications for liquid biopsy are unexplored. We infer detailed reconstructions of
tumor phylogenies in ten prostate cancer patients with fatal disease, and investigate them in
conjunction with histopathology and tumor DNA extracted from blood and cerebrospinal
fluid. Substantial evolution occurs within the prostate, resulting in branching into multiple
spatially intermixed lineages. One dominant lineage emerges that initiates and drives sys-
temic metastasis, where polyclonal seeding between sites is common. Routes to metastasis
differ between patients, and likely genetic drivers of metastasis distinguish the metastatic
lineage from the lineage that remains confined to the prostate within each patient. Body fluids
capture features of the dominant lineage, and subclonal expansions that occur in the
metastatic phase are non-uniformly represented. Cerebrospinal fluid analysis reveals lineages
not detected in blood-borne DNA, suggesting possible clinical utility.
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Prostate cancer is the most commonly diagnosed cancerin men, and is responsible for ~10% of all cancer-relateddeaths in men1,2. The development of cancer within the
prostate leads to a highly heterogeneous state with multiple dis-
ease foci3. These foci either correspond to tumors of independent
origin4 or lineages resulting from evolutionary branches from a
common ancestor5. Despite this intra-prostatic heterogeneity,
evidence from ourselves6 and others7,8 indicates that metastases
share a common ancestral or monoclonal origin in each patient.
The factors that contribute to metastatic potential remain
unclear9. It has been reported that metastatic seeding can occur in
waves from the prostate10 or through metastasis-to-metastasis
seeding, often resulting in polyclonal seeding11. In either scenario,
the metastasizing lineage continues to evolve after initial dis-
semination, leading to heterogeneity between metastases10–12.
The evolutionary pressures affecting metastasising lineages are
undetermined. However, metastases typically demonstrate con-
vergent evolution of AR amplification following androgen
deprivation therapy (ADT)7,13.
These complex patterns of heterogeneity confound our
attempts to accurately predict the eventual metastatic state from
primary samples, and thus determine prognosis and effective
treatment strategies14–16. Indeed, it has been shown that genetic
alterations seen in index lesions identified at biopsy do not
consistently match those in metastases16,17. Similarly, liquid
biopsies have been shown to provide information on clinically-
relevant markers in metastatic disease18, but it remains unclear
how representative they are of the evolutionary path and overall
genomic status of the extant tumor cell population in a given
patient10,19.
To date, most prostate cancer studies involving the direct
reconstruction of evolutionary trajectories from multiple samples
have been restricted to localized disease5, or concentrated on
post-metastatic evolution using predominantly metastatic
samples10,11, typically following ADT20. Combined investigations
of both intra- and extra-prostatic evolution have been limited to
single patients10,13,16. In this study we use deep genomic
sequencing and histopathological information to trace tumor
evolution both within the prostate and during metastasis in ten
men. From this detailed tracing, we aim to reconcile two previous
observations, that multiple metastases commonly have a single
monoclonal origin and that considerable genetic heterogeneity is
observed within and across both primary and metastases. We
then explore the ramifications of our findings in circulating
tumor DNA (ctDNA) derived from blood, as well as tumor DNA
in cerebrospinal fluid (CSF) and urine.
Results
Reconstructing evolutionary origins of metastatic lineages. We
performed deep (average 785X) targeted sequencing of 51 fresh-
frozen samples from 10 men, previously whole-genome
sequenced (WGS)11, in addition to samples from multiple
microdissected regions in formalin or alcohol-fixed samples taken
from the prostate (n= 33), lymph nodes (n= 3), seminal vesicles
(n= 1), bladder (n= 1), and frozen body fluids (n= 24)
including serum, plasma, and CSF. Four of the patients had
undergone radical prostatectomy prior to autopsy, five patients
still had cancer in their prostate at time of death, and one dis-
played no detectable tumor in the prostate at time of death (A34).
Samples were taken at various times throughout the treatment
schedule of each patient, and at rapid autopsy (Supplementary
Figs. 1–10, Methods and Supplementary Data 2).
Targeted regions covered SNVs and indels representative of each
subclone previously identified from WGS11, as well as all coding
mutations (“Methods” and Supplementary Data 4–6). The median
number of mutations per sample used in this study was 705.5, with
range 292–2032. We inferred subclonal structure from all tissue
samples using the DPclust method21 (Supplementary Figs. 1–10),
and constructed phylogenetic trees for all ten men (Fig. 1) following
the Sum and Crossing Rules22 (Methods). As the targets were
drawn from mutations identified in the samples sequenced
previously, it was not possible to infer lineages absent from those
samples. However, the sequencing of additional samples and the
increased coverage enabled the resolution of many more distinct
subclones in both primary and metastatic lineages.
Tumor evolution occurs principally within the prostate. Many
genomic alterations that characterize prostate cancer have been
identified previously7,23. These events were identified in many of
our samples, predominantly occurring prior to metastasis11. In all
cases where multiple primary samples were studied, we identified
branching into multiple lineages within the prostate, either
through phylogenetic tree reconstruction from SNVs (Fig. 1), or
through the identification of distinct copy number alterations
(CNAs) determined from off-target reads24 (Supplementary
Figs. 11 and 12). After metastatic dissemination had occurred,
there were few additional driver events aside from the previously
reported AR amplifications11 and mutations13.
Recently, mutational signatures25 have been used to estimate
chronological timing of evolutionary events26. We adapted this
technique to estimate the proportion of time spent in localized
and metastatic phases of the disease (Methods). With the
exception of A10, this indicated a relatively long period of
monoclonal evolution in the prostate, followed by branching and
then relatively quickly by subsequent metastatic dissemination
(subfigure e, Supplementary Figs. 1–10). In samples where we had
multiple intra-prostatic and metastatic samples, we identified
more distinct subclones within the prostate and local organs than
in the metastases (yellow and brown subclones; top row; Fig. 1).
Furthermore, in patients with multiple intra-prostatic lineages,
each lineage underwent several subclonal expansions in the
prostate prior to initial metastasis, indicated by the chains of
yellow subclones in Fig. 1.
Lineages can be intermixed in the prostate and local organs.
Cross-referencing the phylogenetic trees (Fig. 1) with prostatic
location and histology demonstrated that subclones can exist in
spatially distinct areas, but we also observed subclonal inter-
mixture in A22, A29, A31, and A32, indicating that this is
common. A31, from which we sampled six microdissected
regions (Fig. 2, Supplementary Fig. 13), displayed the most fre-
quent intermixture. We resolved two branched lineages, and three
of the six tumor regions (Z, X, W) sampled contained cells
belonging to both lineages (Fig. 2).
Surprisingly, subclonal intermixture was maintained during
spread to local organs. In A22, cancer samples from the prostate
apex, transrectal biopsy, seminal vesicles and the bladder
contained subclones corresponding to different stages of
common lineages. Several distinct lineages that originated in
the prostate infiltrated the seminal vesicles, where the lineages
identified by subclones 12, 13, and 22 underwent further
evolution before invading the bladder (Fig. 3a). Each of these
lineages spread to local lymph nodes, after which the lineage
including subclone 11 spread to more distant sites. It is uncertain
if all distant metastases from these lineages originated in the
bladder, but the lack of lineages descended from subclones
unique to the seminal vesicles in the metastases indicate this as
the most likely scenario. These observations are consistent
with concurrent trans-prostatic expansion of multiple lineages
from the apex to the base and into the seminal vesicles and
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subsequently the bladder as a single tumoral mass (Fig. 3b).
Similarly, in A10 three different subclones, albeit on the same
lineage, were identified with differing cancer cell fractions (CCF)
between the prostate and the bladder infiltrating metastasis
(subclones 3, 4, and 6, Supplementary Fig. 1), suggesting
simultaneous infiltration by multiple distinct cell subpopulations.
In A10, distant metastases arose from lineages found only in
the primary tumor, and not from invasive spread to the bladder
Fig. 1 Phylogenetic trees of primary and metastatic prostate cancer evolution in ten men. Top row—patients who still had prostate in place at time of
death; bottom row—patients who had undergone radical prostatectomy (A12, A17, A21, A24) or had no discernible cancer in the prostate at time of death
(A34). Patient identifiers are to the right of the root node of each tree, which represents the most recent common ancestor (MRCA) of all tumor cells.
Dotted lines connect the final subclone of a lineage with a letter denoting the sample or samples in which it was observed. Samples connected to multiple
lines arising from different subclones indicates subclonal intermixture in the prostate and local organs, or polyclonal seeding in the periphery. Yellow filled
subclones were observed in samples taken from the prostate. Other colors denote the location of sample in which the subclone was observed as indicated
in the key, where subclones consisting of multiple colors indicate that the subclone was not found in the prostate, but was observed in the metastatic
locations with corresponding colors. Fresh frozen samples are denoted by bold lower case letters in ascending order from a; microdissected fixed samples
are standard upper case in descending order from Z. Letters are colored by sample tissue type. Samples taken from the prostate and local organs are
arranged to the left or right of each tree. Samples taken from distant metastases are arranged horizontally at the bottom of each tree. Visceral (other)
includes adrenal glands (A21, A22, A31), diaphragm (A24), and sigmoid colon (A24). Corresponding sample names, time of collection, cluster information
and locations are given in Supplementary Figs. 1–10 and Supplementary Data 1 and 2.
Fig. 2 Subclones from distinct lineages can be spatially intermixed within the prostate. Six samples were collected across two tissue blocks from
adjacent regions of the prostate. The intra-prostatic portion of the phylogenetic tree of A31 is shown, with lines denoting the final subclone of each distinct
lineage found in the corresponding regions in each slide. Numbered subclones in yellow circles correspond to the clusters shown in Supplementary Fig. 8.
Subclones that correspond to over 50% of tumor cells in a region are designated high proportion, all other subclones present are low proportion. Location
of slides are given in Supplementary Fig. 13.
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(sample Y, Fig. 1). Conversely, distant metastases in A22 appear
to have originated from areas of local spread, although some
lineages remained confined to the seminal vesicles (Fig. 3). Thus,
even where tumor cells were likely present in the seminal vesicle
and bladder for long periods of time prior to death, locally
invasive cells did not always directly progress to distant
metastases.
Distant metastases derive from one intra-prostatic lineage. In
four cases (A12, A17, A21, A29), the phylogenetic trees (Fig. 1)
indicate that all metastases arose from one seeding event from the
prostate or seminal vesicles. In a further three cases (A10, A31,
A34) we observed two seeding events from one lineage, as evi-
denced by metastases derived from two distinct subclones of the
same intra-prostatic branch (Fig. 1).
In A32, all distant metastases contained cells from one lineage
(Fig. 1). In addition, metastatic sample e also contained cells from
a second lineage, at low CCF (0.21). A22 branched into five
lineages within the prostate and local organs (Figs. 1 and 3), and
we traced at least four seeding events. Again, one lineage was
present in all distant metastases (MRCA subclone 12, Supple-
mentary Fig. 5a). Extensive metastasis-to-metastasis polyclonal
seeding occurred within this lineage, but local pelvic lymph node
samples k and h also displayed seeding from a separate lineage
identified by subclone 9 (Supplementary Fig. 5a) at CCF 0.05 and
0.52 respectively. Sample h therefore contains the only major
subclone (CCF > 0.5) that did not arise from the lineage found in
all metastases in any of the 9 patients A10, A12, A17, A21, A22,
A29, A31, A32, and A34. We therefore propose that a lineage
found in all metastases of each patient is dominant, either because
it seeded first or it outcompeted cells from other lineages.
A24 is the only case where we observed branching into two
distinct lineages in the prostate that both seeded metastases
separately. This is evidenced by CNAs identified in samples R and
S that displayed vastly different copy number profiles to the fresh
frozen metastatic samples (Supplementary Fig. 12). Sample R was
a prostate biopsy sample, whereas sample S was a metastatic
sample obtained from a sigmoid colon serosal metastasis removed
during surgery for bowel obstruction 5 months prior to death
(Supplementary Fig. 6b). This means that metastatic sample S
arose from the same lineage as found in R, in contrast to the other
metastases sampled. This patient received radiotherapy to the
prostate bed region three years after prostatectomy (Supplemen-
tary Fig. 6b). As such, it appears that the lineage that seeded S was
eradicated. Indeed, the metastatic samples in this patient showed
enrichment for deletions and balanced inversions characteristic of
radiation-induced DNA damage27, indicating they arose after
radiotherapy treatment.
A similar situation arose in A34, in which we identified two
metastatic seeding events from the prostate. One of these
produced a bone metastasis (e) that required sacral nerve root
decompression, which was performed eleven years prior to death.
However, the phylogenetic tree shows the lineage leading to the
liver metastases resected at autopsy branched from the main
intra-prostatic lineage before the branch leading to the founding
of the bone metastasis (Fig. 1, Supplementary Fig. 10a). This
patient received extensive radiotherapy and anti-androgen
therapy around the time of the sacral nerve root decompression
that caused PSA levels to drop to ~0.1 ng/ml (Supplementary
Fig. 10b). Subsequent platinum-based chemotherapy also caused
PSA levels to drop in this patient, albeit temporarily (Supple-
mentary Fig. 10b). Although radical prostatectomy was not
performed on this patient, no cancer was identified in autopsy
prostate tissue, indicating that this treatment successfully
eliminated disease in the prostate and the lineage that led to
metastasis (e). As such, it appears that the lineage that led to the
liver metastases was present in an undetected state in the
periphery for 11 years. This shows that early seeding can lead to
occult disease that can remain dormant for several years before
becoming active again.
The results of A24 and A34 indicate that two lineages
developed metastatic potential separately, one of which was
eliminated through treatment. It is therefore likely that the





Fig. 3 Multi-clonal invasion into adjacent organs and subsequent metastatic seeding in A22. Subclones identified in each sample were considered in
conjunction with the phylogenetic trees to distinguish invasive local spread, evolutionary progression, and origins of metastatic dissemination. a A
compound phylogenetic/compartmental diagram where lineages can move between compartments (dotted lines, purple= local invasion, orange= distant
spread) and undergo subclonal expansion (solid black lines). Compartments were Prostate, Seminal Vesicles, Bladder and Periphery as labeled. Subclones
are denoted by circles colored by tissue type, with numbers corresponding to clusters in Supplementary Fig. 5. b Spread of metastatic lineage occurred first
through transprostatic migration to the base of the prostate, then to seminal vesicles and then to the bladder. At least one metastatic lineage
(corresponding to subclone 2) was seeded from the bladder, and lineages identified through subclones 4, 11, and 19 may have originated from either the
bladder or seminal vesicles (denoted ‘origin uncertain’). An additional metastatic lineage (subclone 9) appeared to have seeded directly from the prostate.
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Precursors of metastasis differ between patients. We compared
genomic aberrations in the dominant lineage with those in the
lineage confined to the prostate (A10, A31), or was found at low
CCF in a single metastasis (A32). We found multiple genetic
alterations unique to the dominant lineage in each case.
In A31 a number of important events occurred prior to the
branch between the metastatic and intra-prostatic lineages. These
were loss of heterozygosity (LOH) events affecting 6q (covering
MAP3K7), 8p (NKX3-1), 12p (CDKN1B), 13q (RB1), and 17p
(TP53), as well as a focal HD in 10q (PTEN). In the metastatic
lineage, a focal LOH event covering the PPP2R5A gene was
followed by a whole-genome duplication (WGD), and subsequent
single-copy losses of chromosomes 1, 6, 11, 14, 15, and 16. The
intra-prostatic lineage contained alternative driver events: non-
synonymous SNVs affecting TP53 and MLL3; LOH of 16q and
focal LOH events affecting FOXP1 and PDE4B; and amplification
of FOXA1. As these lineages spatially coexisted in the prostate
(Fig. 2), they likely had similar access to blood and lymphatic
vessels.
A10 underwent two branching events that resulted in formation
of perigastric, periportal, and iliac lymph node metastases. The
remaining intra-prostatic lineage continued to develop and
underwent invasion into the bladder, but was not represented in
any of the distant metastases. Analysing shared genomic
alterations between the two metastatic lineages, we observed
separate LOH events covering 8p21 (19,962,013–27,489,421;
Fig. 4). This region contains a number of known driver genes
including NKX3-1. Furthermore, from its absence in the Y and e
samples, we determine that an 8p21 LOH never occurred in the
main prostatic lineage. The presence of LOH covering exactly
the same region (18,632,503–34,083,654) in c and d samples
indicates that it occurred in a common progenitor of lineages in
both samples (subclone 5; Supplementary Fig. 1a). The second
branching event resulted in the lineage observed in transurethral
resection sample Z, which subsequently populated the metastasis
in the iliac lymph node, a. The LOH observed in a displayed
different start and endpoints to the LOH common to c and d
(Fig. 4), indicating that they arose from separate events. This CNA
was not found in sample Z (Supplementary Fig. 14), meaning that
both of the separate 8p LOH events in A10 were only observed in
metastases.
A32 also contained two branching lineages, one of which was
the dominant lineage in all subsequent metastases, and the other
was found in only one metastatic sample (e). Analysis of the
histology of samples corresponding to the dominant lineage
shows tumor cells growing in a perineural region in sample Z
(Fig. 5); such perineural invasion (PNI) is associated with
increased risk of metastasis as it provides a route out of the
prostate28. Indeed, subclones growing around this nerve represent
the most recent common ancestor of tumor cells found across all
metastases. We investigated events that preceded metastasis in
this lineage, and identified a missense mutation (S37C) in
CTNNB1 (from sample X, Y, and Z) in the metastatic lineage,
despite relatively few other differences11.
Evolution occurs linearly after metastasis. Evolution post-
metastasis was consistent with multiple seeding events occurring
from a single continually evolving lineage. This is most apparent
in patient A21, where this lineage is defined by the subclones 15,
14, 11, 12, 10, 9, 16 (Supplementary Fig. 4a). All pairs of
metastases have one of these subclones as a common ancestor.
Similar behavior is also discernible in prostatectomy patients A17
and A24, as well as non-prostatectomy patients A31 and A32
(Fig. 1). Branches that did not share a single-lineage common
ancestor were only observed in A10 (MRCA subclone 5; Sup-
plementary Fig. 1a) and A22 (MRCA subclone 7; Supplementary
Fig. 5). These results suggest that cells from a single dominant
lineage continue to seed most, if not all, metastases after
departing the prostate. The phylogenies of all patients are con-
sistent with this hypothesis. However, it is not clear if seeding
always occurs from a single site (i.e. the prostate in A31 and A32),
or between metastatic sites in sequence29.
These patterns are indicative of linear evolution30, which is
thought to occur when successive driver mutations confer a
selective advantage that allows carriers to outcompete their
ancestors31. In these metastases, there do not appear to be the
selective sweeps that are associated with repeated waves of
positive selection in this model. These results could therefore
indicate negative selective pressure, or may be explained by
particularly favorable access to the circulatory system by the
dominant lineage.
Metastasis-to-metastasis polyclonal seeding is common. Due to
the inclusion of additional samples and the increased resolution
afforded by our deep sequencing, we were able to identify more
cases of polyclonal seeding between metastases than in our pre-
vious study11. Whereas polyclonal seeding was found in five of
ten (A22, A24, A31, A32, A34) cases in the prior study, we found
it occurred in an additional four patients (A10, A12, A17, A21);
the only exception being A29 for which we only have one
metastatic sample and so detection of metastasis-to-metastasis
polyclonal seeding is not possible. This indicates that during
metastasis-to-metastasis transmission polyclonal seeding is the
Fig. 4 Copy number alterations covering the 8p21.3-8p21.2 locus in A10.
Copy number profiles of the 8p region are shown by colored blocks, where
the levels correspond to 1, 2, and 3 copies of the region, and no color
indicates no copies are present. The region subject to loss of heterozygosity
in all metastatic samples is highlighted in pink. Gene names of known
drivers (see “Methods”) in this region are given below, with bars above
detailing the corresponding genomic positions.
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norm. Polyclonal spread in the liver of A34 was detected. The
individual samples were non-contiguous and physically separated
by at least 1 cm, indicating that separate deposits arose from
metastatic spread rather than local expansion.
Variable representation of metastatic DNA in body fluids. To
determine the information available in liquid biopsies, we
examined six types of body fluid sample obtained at various times
in the patients’ treatment cycles: CSF, whole and clotted blood
samples, plasma, serum, and urine. Targeted DNA-sequencing of
the body fluids of eight patients passed QC (Methods). We were
able to identify tumor DNA in fluids derived from blood in all
eight patients, as well as in the CSF of two of these. Urine of two
patients was also sequenced, but we were not able to detect tumor
DNA at sufficient levels for use in subsequent analyses. We cross-
referenced DNA in the blood ctDNA and CSF with subclones
previously identified in the tissue samples to investigate the
representation of the samples in body fluids (Fig. 6; Supple-
mentary Fig. 15).
When cancer subclones were detected in blood ctDNA, the
truncal metastatic clone was always represented, and the
subclones from different metastatic sites are variably represented.
In blood taken at autopsy, in no case did the subclones in the
blood match all known subclones identified in metastases from
the same man. Subclones found only in prostate were never
detected in blood. In 3/8 patients (A10, A12 and A31), we
identified just one lineage in the ctDNA, whereas in 5/8 patients
(A17, A21, A22, A32, A34), we were able to identify subclones
from multiple lineages. Of these, blood samples taken at autopsy
in A22 and A24 displayed subclonal proportions that were
remarkably similar to a single tissue sample (black boxes, Fig. 6),
indicating that this site or one with a similar composition may
have seeded the tumor cells in the blood. One of these was
situated in bone (A22) and the other in a lymph node (A24), so
there is no indication that a particular tissue type is more
amenable to hematological representation.
We sequenced CSF taken at autopsy in two patients: A17 and
A32. In A32, CSF identifies 2/4 of the lineages that were found in
the blood sample, with no additional lineages observed. In A17,
we detected both lineages identified in the blood sample, and an
additional lineage that corresponded to a metastasis in a subdural
region of the cranium (red box †, Fig. 6). The observations of
subclones present in CSF but not in blood, and vice versa,
indicates ctDNA does not freely cross the blood-CSF barrier.
We had blood, serum or plasma samples at earlier time points
in 5 patients. These were A12 – 46 days prior to death (dptd),
A22 – 448dptd, A31 – 1186dptd, A32 – 1080dptd, A32 – 20dptd
and A34 – 4040dptd. Of these, only the A31 – 1186dptd and A32
– 1080dptd samples did not display mutations consistent with the
previously identified subclones. The subclones identified in the
A12 – 46dptd and A32 – 20dptd were the same as those observed
at autopsy, as was the A22 – 448dptd sample, although this was of
poor quality. Remarkably, the A34 – 4040dptd sample contained
subclones 15 and 13 that corresponded to the same lineage as the
spinal metastasis that was removed 11 years prior to death (red
box *, Fig. 6). These subclones were not observed in body fluid
samples at autopsy, providing evidence that this lineage was
eliminated by treatment (Supplementary Fig. 10b).
Discussion
These findings provide numerous insights into prostate cancer
evolution both intra-prostatically and during metastatic dis-
semination. It is clear that each individual cancer evolves in a
unique way. However, there are some commonalities between these
evolutionary trajectories. In particular, we consistently observe the
development of multiple intra-prostatic lineages prior to the
emergence of one dominant lineage that seeds many, if not all, of
the subsequent metastases. This indicates that metastatic prolifera-
tion is relatively rare and likely subject to strong selective pressure.
In these advanced-stage cancers, extensive local disease was
present. We found that divergent lineages spatially coexisted in
the same regions of cancer within the prostate. These results
Fig. 5 Metastasis-capable cells in multiple sites within the prostate and perineural regions in A32. The prostate (center) was divided into 13 slices
(black lines) and three regions were sampled, two from slice 10, and one from slice 6. The purple circle denotes the region that was fresh frozen and
sequenced as sample c and the red circles denote regions that were ethanol/methanol fixed and paraffin embedded. Histology slides shown to left and
right, with microdissected regions highlighted in cyan with adjacent sequencing sample letters. The lower pane shows the phylogenetic tree of the intra-
prostatic evolution, with numbers in the circles corresponding to subclonal clusters as derived in Supplementary Fig. 9. Lines joining the miscrodissected
regions to a subclonal cluster indicate the final subclone observed in each region; these are designated as high (CCF > 0.5) and low (CCF < 0.5) proportion.
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contrast with those from studies of pancreatic32, renal33, glio-
blastoma34, and lung cancers35, where subclones were spatially
distinct. We also found this subclonal intermixture was main-
tained during invasive spread to local organs. Remarkably, when
spread to local organs was observed, these lineages did not
necessarily lead to distant metastasis. Similar behavior has been
observed in pancreatic cancer32, where metastatic colonization of
the peritoneum and distant metastases are seeded by different
lineages. If the locally invasive lineage is not always the metastatic
lineage, stage T3 (extracapsular extension) may be an indirect
marker for advanced disease, rather than a direct measure of the
likelihood of metastatic dissemination.
We found that the majority of driver aberrations occurred in
the trunk of the evolutionary tree. Branching into multiple
lineages then occurred, after which one lineage initiated meta-
static expansion. The metastatic and non-metastatic lineages
therefore displayed relatively few differences, enabling the item-
ization of individual putative driver events. Lineages that did not
metastasize continued to accumulate additional driver aberrations
after diverging from the metastatic lineage. This was most notable
in A31, where the non-metastatic lineage experienced six distinct
known driver aberrations, compared to just 2 in the metastatic
lineage. These results indicate that full metastatic potential does
not arise through the cumulative onslaught of a large number of
driver events, but rather the accumulation of a set of synergistic
aberrations.
It is therefore possible that genetic factors, i.e., either or both of
the heterozygous loss of PPP2R5A or the WGD, provided the
crucial functional step toward metastatic potential in A31. This
is further evidenced by the finding that WGD is significantly
enriched in prostate cancer metastases compared to primary
tumors36. Furthermore, we also found similar putative ‘metastatic
trigger’ events in A10 and A32. Metastatic lineages in A10 dis-
played convergent evolution of LOH events affecting a small
region of 8p covering the NKX3-1 gene, which has been asso-
ciated with aggressive disease37. This could indicate that this LOH
was sufficient to initiate metastatic dissemination in this patient.
In A32, we found the MRCA of cells in all metastatic lineages
resided in a perineural region in the prostate; these had experi-
enced a CTNNB1 missense mutation. CTNNB1 is a known driver
gene that codes for the β-catenin protein, a component of the
extra-cellular matrix38 and a constituent of the Wnt signaling
pathway39. The precise mechanisms of perineural invasion
remain unclear40, but it is well established that aberrant expres-
sion of Wnt/β-catenin targets MMP2 and MMP9 lead to an
increased proclivity for perineural invasion in pancreatic can-
cer41. It is plausible that this genetic alteration facilitated spread
to the perineural space, from where it seeded to distant sites. The
accumulation of genetic alterations was very different across these
three patients, indicating that there is no common route to
metastasis. These results suggest that tumor evolution in the
prostate leads to a primed state, after which the acquisition of a
key genetic alteration could tip the balance toward metastasis. It is
also possible that epigenomic or other unmeasured factors con-
tributed to the development of metastatic potential in these
patients. It is likely that metastatic trigger events are rare and arise
stochastically, which means it will be difficult to predict the
lineage that will eventually metastasize.
Metastatic potential appeared to develop twice in two patients.
In A34, the lineage that metastasized to the liver diverged from
Fig. 6 Subclones in tissue samples can be identified in DNA obtained from liquid biopsy. Plots showing the proportion of single nucleotide variants
corresponding to each subclone (numbered on x-axis) that are observed in each sample (letters on y-axis). The area of the circle is proportional to the
cancer cell fraction (CCF) of the subclone, with CCF of 1 found in the leftmost (truncal) nodes of the subplot. Anatomical location of tissue samples are also
given in the sample label, and colored as in the legend. Body fluid samples are denoted by the time when the sample was taken (Aut= autopsy, dptd= the
number of days prior to death), and the type of fluid (Serum; Plasma; blood, either Clotted or Whole; Cerebrospinal fluid (CSF)). Sample locations in bold
are those that contain lineages represented in liquid biopsy at the highest CCF. Tissue samples in black boxes were polyclonal mixtures and contained
similar subclonal CCFs to the boxed body fluid sample. Red boxes denote subclones of interest: star denotes subclones corresponding to a lineage found
only in a spinal metastasis and serum, both of which were extracted 4040dptd, and dagger denotes a subclone that is only observed in a subdural
metastasis and CSF.
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the intra-prostatic lineage at a higher position (nearer the root
node) than the spinal cord metastases that were removed 11 years
prior to death. In A24, the cancer in the sigmoid colon serosal
sample was not from the same lineage that led to the systemic
metastases. As A24’s pelvis was treated with radiotherapy, it
appears that this treatment eliminated the metastatic potential of
this lineage. The substantial amount of time to death after these
lineages branched in the prostates of these patients (at least 11
and 10 years respectively) provides further support that evolution
of metastatic potential is a rare event.
Both tissue and liquid biopsy may be of limited utility in
assessing overall metastatic status. Information available from
tissue biopsies will be incomplete, due to the presence of multiple
intra-prostatic lineages, and there is currently no means to
identify which lineage is most likely to metastasize. However, the
fact that evolutionary branching usually precedes metastatic
seeding means that heterogeneity could be used as a marker for
advanced disease. This may explain the findings of a previous
study, which showed that subclonality in the prostate is indicative
of poor prognosis42. The ctDNA detected in the blood did not
give a full representation of extant metastatic lineages, but it did
display subclones corresponding to the dominant lineage in all
cases. It may have been possible to identify cells from more
metastatic sites using more sensitive analysis of individual cir-
culating tumor cells43. Nonetheless, the variable representation of
metastatic subclones does indicate that the circulating systemic
tumor burden only originates from a subset of metastatic sites. In
two cases (A24 and A34) the disappearance of a lineage found
earlier in the blood appears to be a true indicator of therapeutic
response, which could be useful in designing clinical trials aimed
at evolutionary steering of tumors to beneficial outcomes. The
discovery of metastatic lineages in CSF not found in ctDNA
indicates that a combination of CSF and blood liquid biopsies
could provide a more accurate assessment of metastatic status in
prostate cancer patients. Our study strongly indicates that ana-
lysis of autopsy and/or multiple metastases together with liquid
biopsy results will be critical to determining when and how liquid
biopsy should be utilized in general clinical practice.
The 10 men who are the subjects of the study received treat-
ment for prostate cancer between 1987 and 2005 (Supplementary
Figs. 1–10). These ranged from drug-free (radiotherapy and
orchidectomy in A32) to multiple androgen-manipulating and
chemotherapeutic agents varying both in type and intensity. The
standard of care for prostate cancer has changed in the inter-
vening years. However, many of the drugs they received, such as
leuprolide and flutamide, are in the same class as currently used
drugs. It is remarkable that despite differences in treatment
received, they all showed similar evolutionary patterns in the
prostate and metastatic periphery as reported above. Therefore
we believe the results will be relevant to men treated with modern
therapies, and this cohort of deeply studied men can serve as a
benchmark for comparison of tumor evolution under selective
pressures applied by newer pharmaceutical agents in future
studies.
A detailed picture of the evolution from primary to metastatic
prostate cancer is now emerging. Considerable intra-tumoral
heterogeneity is commonly acquired from several years of growth
within the prostate, extending through local invasion into the
seminal vesicles and bladder. Selection, frequently acting at the
genetic level, enables cells from a single lineage to escape the
prostate and colonize distant sites. This seeding event is followed
by the re-emergence of heterogeneity, albeit just within the
metastatic lineage, which is rapidly distributed across multiple
sites through polyclonal migration.
Methods
Study materials. Tissue samples were collected as part of the PELICAN integrated
clinical-molecular autopsy study of lethal prostate cancer. The 10 patients included
in this study consented to participate in the John Hopkins Medicine IRB-approved
study between 1995 and 2005. The mean age of the study subjects at the time of
diagnosis of prostate cancer was 61 years. Samples studied were from surgical
samples, body fluid, and autopsy samples collected at multiple time points between
1987 and 2005. A summary of patients, samples, and targeted regions included in
the study is shown in Table 1. Additional characteristics of the study patients,
including clinical timelines and samples are contained in Supplementary Figs. 1–10,
Supplementary Data 2 and 3, and Gundem et al.11 supplementary information.
A total of 163 samples, including 37 body fluid samples (including whole blood,
plasma, serum, CSF, pleural fluid, pericardial fluid, and urine), 53 high molecular
weight (HMW) samples from microdissected frozen tissue (new aliquots of same
DNA used in Gundem et al.11), and 73 laser-microdissected paraffin-embedded
(PE) tissue samples were included in the study.
Body fluid samples obtained from the 10 men during life and at autopsy are named
according to source (serum, plasma, whole blood, CSF, pleural fluid, pericardial fluid,
and urine), and sampling days prior to death (dptd) from prostate cancer.
PE tissue samples were from prostate biopsy, radical prostatectomy,
transurethral resection of the prostate (TURP), from prostate removed at autopsy,
or from other surgery as indicated in Supplementary Data 2. PE tissue samples
were either formalin-fixed paraffin-embedded (FFPE) or alcohol-fixed paraffin-
embedded (AFPE) with ethanol/methanol fixative (3:1 EM)44 as indicated
(Supplementary Data 2). One laser-microdissected FFPE autopsy sample (A10-
20322-BladderInfiltMET) is also included in the current study. PE regions of
interest (ROI) in available tissue sections were chosen based on anatomic location
and morphology, including tumor areas of variable morphology, noncancerous
areas as technical controls to test for DNA cross contamination in paraffin tissue,
benign prostatic hypertrophy (BPH), and some tiny prostate intraepithelial
neoplasia (PIN) regions. Multiple regions of a primary prostate cancer were laser-
dissected from patients A24, A31, A32, and A34 samples. In total, prostate samples
from at least one-time point (biopsy, radical prostatectomy, transurethral resection,
or autopsy) were analyzed for all 10 patients. Images of laser-dissected regions in
PE tissue are contained in Supplementary Data 3.
Autopsy body fluid samples were collected using needle aspirations of blood
from the right ventricle and CSF from the 4th cerebral ventricle using sterile
methods. Because postmortem clotting separates clotting components and many
nucleated cells from the remainder of the blood, liquid blood removed from the
right ventricle at autopsy is referred to as “whole blood” but is typically lower in cell
content than whole blood removed during life. Urine collected during life was
collected by clean-catch midstream sampling, while urine collected at autopsy was
collected by sterile suprapubic bladder aspiration. PE tissue blocks were stored at
room temperature and body fluid samples were frozen at −80 °C prior to DNA
isolation.
Patients’ detailed clinical histories were obtained from medical records curated
from all available hospital and clinic records and in some cases the patient’s own
diaries provided directly to the study team. Time from prostate cancer diagnosis to
Table 1 Summary of patients and samples included in the study.
Study patient A10 A12 A17 A21 A22 A24 A29 A31 A32 A34
Years between diagnosis and death from metastatic prostate cancer 4 4 4 5 2 11 15 8 9 12
No. target subs 675 266 958 959 2258 703 362 714 1733 1094
No. targeted indels 147 72 163 124 233 209 59 115 263 234
Total no. of mut. analyzed 728 309 870 850 2032 509 466 292 683 1133
No. samples in Gundem et al.11 4 3 5 8 10 4 2 5 5 4
No. samples in current study 10 19 14 19 15 22 6 18 16 11
No. of sample time points 2 3 3 2 3 3 3 3 4 3
Additional details in Supplementary Data 2 and 3.
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death ranged between 2 and 15 years. In six men, the microdissected prostate
material studied (frozen, FFPE and 3:1 E:M fixed) was removed at autopsy, and the
other four patients (A12, A17, A21, and A24) underwent radical prostatectomy
soon after the initial diagnosis of prostate cancer and FFPE material from these
men was laser-microdissected and studied. In addition, prostate biopsy samples
from patients A17, A22, A24, and A29 were laser microdissected and included in
the study.
We also analyzed a frozen spinal cord root-compressing sacral bone metastasis
sample surgically removed 11 years prior to death from patient A34 (A34-21408),
224 days (7.5 months) after biopsy diagnosis, and laser-dissected FFPE TURP
samples removed due to bladder outlet obstruction from patients A10 and A34.
Blood samples taken prior to death were collected from A12 (46 dptd), A22 (448
dptd), A31 (1186 dptd), A32 (1040 dptd and 20 dptd) and A34 (4040 dptd). Blood
samples taken during autopsy are available for A10, A12, A17, A22, A24, A31, A32,
and A34. Other liquid samples, e.g. urine and CSF, were analyzed for A17 (CSF
from autopsy), A29 (urine from 409dptd and autopsy and CSF from autopsy), A31
(urine from 675 dptd and autopsy) and A32 (urine from 655 dptd and CSF from
autopsy).
Sample tracking. A laboratory database system was used to maintain traceability
of each DNA sample from the time of autopsy, through cryostat or laser micro-
dissection (LM), analyte isolation, storage, shipping, assays, analysis, and EGA data
repository submission as described below.
Cryostat microdissection and DNA isolation (frozen tissue samples). Tissue
blocks embedded in OCT (Optimal Cutting Temperature compound, Tissue-Tek)
were serial −20 °C cryostat microdissected for histological tumor purity >75%.
During serial dissection, prior to isolation of sections for DNA extraction, OCT
compound was trimmed away completely. HMW DNA was isolated from 50 to
500 six micron sections per dissected tissue block using proteinase K digestion and
phenol/chloroform extraction.
LM and lysate preparation (PE tissue samples). For each tissue block studied, 4
µm face sections were stained with hematoxylin and eosin (H&E), scanned with
Aperio whole slide scanner, and ROI in each digital image were annotated for
dissection (Supplementary Data 3). For cases A10, A12, A17, A21, and A22, 5 µm
sections on glass slides were microdissected. For cases A24, A29, A31, A32, A34, 7
µm thick serial sections mounted on framed PEN membrane slides (Molecular
Machines and Industries) were microdissected. Just prior to microdissection, slides
were incubated in xylene (5 min.x2), dehydrated in 100% ethanol (1 min.x2),
stained with cresyl violet acetate and eosin mix45 for 30 s, dehydrated in 100%
ethanol (30 s.x2), cleared in xylene (3 min.x2), dried in fume hood for 5 min and
kept in a desiccator for 1 h prior to LM. ROI were dissected from membrane slides
by laser cutting on MMICellCutPlus (Molecular Machines & Industries) instru-
ment, and from archival glass slides by manual microdissection of laser annotated
ROI using a Leica MZ8 dissecting microscope46.
Lysate preparation (PE samples). Lysates containing DNA were generated from
microdissected tissues using PicoPure DNA Extraction Kit digestion buffer
(Thermo Fisher) by incubating samples at 56 °C for 68 hours with the addition of
10 µl of 20 mg/ml Proteinase K (Thermo Fisher) every 24 h. Samples were then
heated to 95 °C for 10 min to inactivate Proteinase K.
Isolation of DNA from body fluids. QIAamp circulating nucleic acid kit 55114
(Qiagen) was used to isolate DNA from serum, plasma, CSF, and urine. QIAamp
DNA blood midi/maxi kit 51185 (Qiagen) was used to isolate DNA from whole
blood, and pleural fluid. Both kits were used following manufacturer’s protocols.
Double strand library preparation (frozen and body fluid samples). 12.3 to
96.1 ng of gDNA, quantified with Qubit dsDNA BR Assay kit (Thermo Fisher
Scientific), was fragmented with Episonic Multi-Functional Bioprocessor 1100
(Epigentek Group Inc., Farmingdale, NY, USA). The libraries were created with
Thruplex DNA-seq 96D kit (Rubicon Genomics) according to manufacturer’s
protocol. 10–50 ng of DNA was used for library preparation. Five amplification
cycles were used. The amplified libraries were purified with 50 µl of NucleoMag
NDS Clean-up and Size Select beads and eluted to 30 µl of PCR grade water. The
libraries were quantified with LabChip GX HT DNA HiSens chip (PerkinElmer,
Waltham, MA, USA) (Supplementary Data 2).
Single strand library preparation (PE samples). Five to 150 ng of lysate gDNA
was quantified with Qubit dsDNA BR Assay kit (ThermoFisher, Waltham, MA,
USA) and fragmented with Episonic Multi-Functional Bioprocessor 1100 (Epi-
gentek Group Inc., Farmingdale, NY, USA). The libraries were created with Accel-
NGS 1S Plus DNA Library Kit (Swift Biosciences, Ann Arbor, MI, USA) according
to manufacturer’s protocol. Four to 40 ng of DNA were used for library prepara-
tion. Seven amplification cycles in PCR were used for all the samples. Agencourt
AMPure XP beads (Beckman Coulter, Brea, CA, USA) in 1.8 times the reaction
volume were used for purifications. 1S Plus Dual Indexing Kit was used for all the
samples. The libraries were quantified with LabChip GX HT DNA HiSens chip.
Custom capture target selection. From the whole-genome sequencing (WGS)
data (based on 51 fresh frozen samples) produced in Gundem et al.11, we selected a
subset of 12257 variants (substitutions and indels) representative of the phyloge-
netic evolution in 10 metastatic prostate cancer patients. In the selection process,
first, the mutations located in UCSC repetitive regions were excluded. Then, a
random subset of the variants was sampled from each mutation clone (a cluster
identified by the Dirichlet Process clustering algorithm, i.e., a branch on a phy-
logenetic tree) representing each clone. The resulting random subset contained
11,135 variants. The final set of targeted mutations additionally included all 1122
protein-altering variants producing the targeted set of 12,257 variants. Targeted
regions for sequencing were produced by adding 110 nucleotide flanks to each
indel target and flanks of 60 nucleotides were added to the substitution target
positions. A greater targeted area for indels was chosen to avoid false-positive indel
calls due to misalignment. To prepare the final set of targeted regions, all over-
lapping regions (n= 370) were merged, resulting in 11,886 regions that covered
1.58 Mb. This set of targeted regions was used in the Nimblegen probe design,
which produced 12,445 baits (580 targeted regions were covered by 2 baits, with 13
baits covering 2 target regions). Overall targeted genomic regions and targeted
coding indels and coding substitutions are listed in Supplementary Data 4–6.
NimbleGen SeqCap EZ custom capture. Four to 15 samples were pooled to each
capture reaction. Equal nanograms of each library were in each pool (13–40 ng per
sample). The capture was performed according to SeqCap EZ Library SR User’s
Guide v5.0 protocol with the following exceptions using SeqCap EZ Choice Library
(Roche Sequencing, Pleasanton, CA, USA). For the test samples HE oligos were
used and for the dual index libraries 1 µl per xGen Universal Blocking oligo Truseq
HT-i7 and i5 (Integrated Device Technology, San Jose, CA, USA) were used instead
of the HE oligos. Ten cycles were used for post-capture amplification instead of 14.
The captured and amplified pools were quantified with 2100 Bioanalyzer High
Sensitivity DNA Analysis Kit (Agilent Technologies, Santa Clara, CA, USA).
Sequencing. The libraries were sequenced in HiSeq1500 and HiSeq2500 instru-
ments using paired-end 101 cycle V4 high output chemistry and paired-end 101
cycle V2 Rapid run chemistry (Illumina, San Diego, CA, USA). Targeted
sequencing data was obtained from 150 of 163 total samples collected from the 10
patients with an average coverage of 785.7× (range 64.9–2253.2), as described in
the Sample Qualification section below and in Supplementary Data 2.
Preprocessing and alignment of sequencing data. Bioinformatic processing was
performed following an established protocol47. Specifically, raw reads were cor-
rected for low base-calling quality, Illumina adapters, and short length using
Trimmomatic48 (with parameters: leading= 3, trailing= 3, sliding window= 4:15,
illumineclip= 2:30:10, and minlen= 36). Quality trimmed paired-end reads were
aligned to the human reference genome build GRCh38 with BWA-MEM49 and
alignment files sorted by coordinate and marked for duplicates with Picard tools50.
The Genome Analysis ToolKit (GATK)51 tools were then run to perform base
quality recalibration and realignment of indels. Finally, alignment files from the
same biological sample were merged and duplicate reads were remarked using
Picard tools50. Quality control analysis was performed using FastQC52 with default
settings. The GATK resource bundle files used in the process were converted from
GRCh37 to GRCh38 using CrossMap53 and chain files downloaded from
EnsEMBL. Default parameters were used unless specified otherwise.
Variant calling. For variant calling, the last two bases from each alignment were
removed using the trimBam function of the bamUtil50 tool. Each tumor sample
was then paired with its patient-matched control sample that had been WGS earlier
in Gundem et al.11 and variants were called using GATK MuTect251. Default
parameters were used, except that down sampling and filtering of duplicate reads
were disabled and clustered_events flags were cleared to utilize all deep-sequenced
coverage data. Finally, variants were filtered against a panel of normals generated
from samples from healthy patients, and by discarding those that were not within
panel’s target regions+/− 150 bp. De novo mutation calling was performed, and
SNVs were used in the analysis if they were called separately in two or more
samples.
Sample qualification. Summary qualification results for 163 samples entering the
sequencing process are contained in Table 2, and are detailed in Supplementary
Data 2, 3, and 7. Seven body fluid and six microdissected PE samples failed library
preparation, most likely due to DNA fragmentation and low DNA concentration.
For the remaining 150 samples from which data were analysed, samples are divided
into EGA datasets A (118 samples) and B (32 samples). Samples in EGA dataset A
are illustrated in the main figures and are grouped together to illustrate the main
findings. Some of the body fluid samples in EGA dataset A contain low cancer
variant signal and are included as comparison to later samples from the same
patient with strong signal in body fluids. A29-21276-AutCSF data displayed
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evidence of possible contamination by extraneous human DNA and was excluded
from the anaysis, but is included in EGA dataset A as there are still observable
tumor variants irrespective of contamination. The 32 samples in EGA dataset B
containing low signal or ancillary findings and are accessible on EGA for
researchers who may wish to further examine them.
The results from samples in EGA dataset B are illustrated in Supplementary
Data 7 and include 5 body fluid samples (A22-21268-AutClottedBlood, A29-
21274-409dptdUrine, A29-21275-AutUrine, A31-21279-675dptdUrine, and A31-
21283-AutUrine). A22-21268-AutClottedBlood exhibited a background noise
pattern. The four other body fluid samples in EGA dataset B are urine samples, one
of which contains cancer variant signals similar to portions of the primary tumor
(A31-21283-AutUrine). The other three urine samples (A29-21274-409dptdUrine,
A29-21275-AutUrine, A31-21279-675dptdUrine) show mainly a noise pattern.
These data are interesting and indicate that DNA from primary prostate cancer can
be detected in urine at times, but the data are limited to only one positive and three
samples that show mostly noise and are left out of the main findings for brevity.
The one frozen tissue noncancerous sample in EGA dataset B (A21-21091-
LKidneyNL-PD12337b) is a technical control.
For the 67 microdissected PE samples included in the study, 21 noncancerous
controls were included. PE samples are infused with several liquids during
collection and processing, making them potentially more susceptible to pre-
sectioning DNA cross-contamination than frozen tissue samples. Seventeen of 21
PE samples considered to be noncancerous prostate control samples prior to laser
dissection showed no evidence of cancer DNA variant signal. Results from these
samples show what we interpret as noise (<50% SNVs with CCF > 0 in a cluster) in
terms of detected cancer-specific variants, as illustrated in clustering figures shown




A21-20348-3RHPBPH, A24-20443-PINAreaA, A24-20447-PINAreaB, A24-20449-
BiopsySite, A24-20450-ProstateInkedMarginA, A24-20451-NontumorAreaA, A24-
20452-NontumorAreaB, and A24-20458-ProstateInkedMarginB.
Four PE samples (A10-20321-TURPNL, A29-20462-BxNoncancerousEpithelium,
A31-20470-NontumorMuscle, A34-20479-NontumorStroma) were defined as
noncancerous prior to laser dissection and show cancer variant signals in cluster
diagrams shown in Supplementary Data 7. Pathology review of the whole slide image
ROIs for these samples shows that these samples are likely to contain small numbers
of cancer cells detected by the deep targeted sequencing performed in this study.
In A10-20321-TURPNL noncancerous ROI dissected from 8 TURP chips are in
close proximity in many areas to high-grade infiltrative cancer. The presence of
subclones 12–16, also present in the A10-20320-TURPCAGL5 from this patient, is
not surprising. The portions of 8 TURP tissue chips dissected each has close
proximity to high-grade prostate cancer regions in the same TURP chip, and it is
likely that when these regions were dissected from adjacent glass slides, some
cancer cells were included. Cross-contamination of the sample after extraction
from A10-20320-TURPCAGL5 to A10-20321-TURPNL is ruled out because of the
presence of subclone cluster 9 in 20320 that is absent from 20321.
In A29-20462-BxNoncancerousEpithelium, the cancer variant cluster data from
this sample shows a low-level cancer variant signal. Review of the ROI selected for
laser dissection shows four foci of suspicious cells likely to be prostate cancer that
was not appreciated prior to the dissection. Our interpretation is that this faint
signal comes from a small fraction of tumor cells sequenced at high depth. Note
that the tissue block dissected in this case had regions of cancer in it that had
disappeared when deeper sections were cut, so it is not unexpected that some
cancer cells are in the ROI and likely in the adjacent dissected slides.
In A31-20470-NontumorMuscle, the right side of the defined ROI selected for
laser dissection comes within 100 microns of visible cancer cells. Since the cancer
variant cluster figure shows a faint primary cancer signal in this sample, it seems
most likely that the regions dissected from adjacent slides contained a small
amount of cancer.
A34-20479-NontumorStroma is similar to A10-20321-TURPNL in that it also
is from a TURP sample with a large amount of surrounding high-grade cancer. In
addition, the right side of the single TURP chip dissected for this sample has two
tiny foci of suspicious cells that likely account for the faint cancer signal in the
cluster figure for this sample.
Of 42 primary prostate cancer regions dissected from PE tissue, 5 gave scant signal
consistent with low quality or quantity of DNA and these are included in EGA dataset
B. All five are from tissues that were formalin-fixed. These are A21-20346-3RHPCA
GL3, A21-20349-3RECAGL3, A21-20350-3RECAGL4fusedpapillary, A21-20356-3LC
CAGL3, and A24-20461-BxNontumorandtinyquestionableareas. The latter sample
(20461) is from a tiny partially crushed prostate biopsy region and does show signal
above background consistent with primary tumor, but we judge the signal too limited
to make firm conclusions about evolution.
Tumor cellularity estimation. For the 51 samples that were previously sequenced
with WGS, we used the WGS-based purity estimates generated with the Battenberg
algorithm (https://github.com/cancerit/cgpBattenberg). For the 97 new samples
sequenced with targeted sequencing, tumor cellularities were estimated using a
combination of two methods: based on the variant allele frequency information
and the Dirichlet Process (DP) clustering algorithm. The initial estimates were
calculated as the mode of the Gaussian kernel density function fitting the dis-
tribution of VAFs of truncal mutations for each sample. VAFs lower than 1% were
excluded from this estimation, as they likely correspond to false-positive variant
calls. All samples were considered to be diploid, except for the samples from A31
and A32, which were treated as tetraploid based on the average sample ploidy
estimated by the Battenberg algorithm in Gundem et al.11. A subsequent fine-
tuning of the estimated sample tumor cellularities was done based on the data from
the Dirichlet Process clustering algorithm as in Gundem et al.11. The cellularity
values were modified so to achieve values of CCFs approximately equal to 1
(between 0.75 and 1.25) in the truncal cluster produced by the DP clustering
algorithm.
Copy number estimation. CNA in the studied samples were estimated using
CNVkit24 to estimate copy number profiles using the off-target reads in our tar-
geted sequencing data. To construct pooled copy number references required by
CNVkit in the read count normalization, we used samples with the estimated CCF
lower than 1%, i.e., non-tumor samples. Body fluid samples not containing
traceable amounts of cancer cells were used in the reference for both tumor con-
taining body fluid and HMW fresh-frozen tissue samples. For the PE tumor
samples, non-tumor FFPE samples were used in the reference. To produce final
copy number profiles, log-ratios provided by the CNVkit were converted into
clonal copy number estimates with correction for sample’s CCF and ploidy using a
formula as in Adalsteinsson et al.54. For the FFPE and BF samples the ploidy values
to be used in the copy number estimation were obtained by comparing the CNVkit
copy number profiles to the copy number profiles of the HMW samples obtained
with the Battenberg algorithm. Only clonal copy numbers from the HMW copy
number profiles were used in the comparison. To estimate the correct ploidy value
for each sample we explored a range of possible ploidy values, from 2 to 5 with step
of 0.1. The ploidy value producing the highest match between the estimated copy
number profile with one of the copy number profiles of the HMW samples of the
Table 2 Sample summary.
Samples Entering study Failed library prep EGA dataset A EGA dataset B
Body fluid 37 7 25 5
(Serum 12, plasma 7, whole blood 5,
CSF 3, urine 6, pericardial fluid 2,
pleural fluid 2)
(Plasma 1, urine 2,
pericardial fluid 2, pleural
fluid 2)
(Serum 12, plasma 6,
whole blood 4, CSF 2)
(Whole blood 1, urine 4)
Frozen tissue 53 0 52 1







73 6 41 26
(Metastatic PCa 9, primary PCa 42,
normal prostate 18, normal lymph
node 1, BPH 2, PIN 1)
(Metastatic PCa 1,
primary PCa 4, normal
prostate 1)





Total 163 13 118 32
Sequence data from 150 samples where library creation succeeded were analysed and are submitted to EGA. 118 samples central to findings presented in the main text are contained in EGA dataset A.
Data from 32 samples with important background control and other findings are included in EGA dataset B and are discussed in the Sample Qualification section and detailed in Supplementary Data 2, 3
and 7.
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same patient was selected. As the majority of the analyzed samples were obtained at
the earlier time points compared to the WGS analyzed autopsy samples, the
mismatching copy numbers were considered to be correctly estimated if they were
equal to 2, i.e., corresponding to the copy neutral regions.
As a quality control we compared copy number profiles of the HMW samples
estimated with CNVkit from the targeted sequencing data and Battenberg from the
WGS data. In the comparison there were three outliers due to a big difference
between ploidy values used in the copy number estimation, i.e. sample-specific in
the Battenberg and patient-specific in the CNVkit estimations. The patient-specific
ploidy values used by CNVkit were based on the majority of the rounded ploidy
values from the WGS HMW samples analyzed in Gundem et al.11 with Battenberg.
The three outliers are A12-c, A21-f, and A29-a with their Battenberg and CNVkit
specific ploidies correspondingly: 4.47 vs 2, 3.76 vs 2, and 4.92 vs 2.
Excluding the three outliers mentioned above, the percentage of the bp in the
autosomes with the same copy number estimated by both methods ranged from
46.24 to 93.11% with the mean at 78.13% and median at 83.13%. The comparison
was performed only in the autosomes as both methods produce less reliable
estimations in the sex chromosomes.
CCF estimation. The CCF was calculated by adjusting the variant allele frequencies
with copy number and tumor purity following the method in Bolli et al.21. In brief,
the mutation copy number, nmut, equivalent to the fraction of tumor cells carrying
a given substitution multiplied by the number of chromosomal copies of the




ρntlocus þ nnlocus 1 ρð Þ
 
;
where fs is the fraction of mutated reads observed in the sequencing data, and ρ,
ntlocus and nnlocus are respectively the tumor purity, the locus-specific copy number
in the tumor cells and the locus-specific copy number in the normal cells. For all
mutations in amplified regions with major copy number C, the observed number of
mutant and wild-type reads was compared against the expected fs values resulting
from the mutation being present on 1, 2, …, C chromosome copies, assuming a
binomial distribution, and nchr was assigned the value of C with the maximum
likelihood. CCF was then calculated as nmut/nchr.
SNVs in fixed samples were only retained if found in CNV regions called with
CNVkit that agreed with those called by the Battenberg algorithm in at least one
HMW sample.
Mutation clustering. The Dirichlet Process clustering (DPClust) method21 was
used to group mutations present at similar CCF in each tumor sample. DPClust
was performed for each patient on the samples with estimated tumor cellularity
above 15%. The DP clustering corresponded to a model defining mutations as
originating from an unknown number of subclones contributing to a tumor in
unknown proportions and represented by an unknown fraction of tumor cells. To
perform the analysis, we used the DPClust package available from Github (https://
github.com/Wedge-Oxford/dpclust) version 2.2.5, run for 10,000 MCMC itera-
tions, of which 9000 were burn in. Other parameters were conc_param= 1,
cluster_conc= 5, density.smooth= 0.001, max.burden= 1.5. The output of
DPClust is a set of subclones, each of which has an associated CCF within each
sample analyzed and the number of mutations associated with that subclone
(Supplementary Data 1).
Phylogenetic tree construction. Patient-specific phylogenetic trees incorporating
mutation clusters identified by DPClust were manually constructed using the Sum
and Crossing Rules22. In brief, the sum rule operates upon the premise that if the
CCFs of two mutation clusters in any sample add up to more than the CCF of their
shared ancestral cluster, they must be collinear. The crossing rule states that if two
mutation clusters B and C are descendants of mutation cluster A, and if cluster B
has higher CCF than cluster C in one sample and cluster C has higher CCF than
cluster B in another sample, clusters B and C must be branching. Underlying the
Sum and Crossing rules is the Infinite Sites Assumption, which states that each
mutation has occurred only once. In practice, a very small number of positions in
the genome may be subject to mutation more than once, but this occurrence
is sufficiently rare that it does not impair our ability to define mutation clusters. In
general, the sum and crossing rules do not restrict the space of possible trees to a
single candidate. However, when applied simultaneously to the CCFs of mutation
clusters across multiple samples they severely constrain the space of possible
trees. In cases where branched or sequential assignments could not be definitively
distinguished, which only occurred in the leaves of the trees, we followed
the corresponding tree obtained from WGS in Gundem et al.11. Clusters with a
mean CCF < 0.02 or containing over 50% indels were not included in tree
construction.
Putative drivers on chromosome 8p. We report gene names of known drivers on
8p in Fig. 4. These were defined as those genes listed on Cancer Genetics Web
chromosome 8 (http://www.cancer-genetics.org/clinkc08.htm, accessed 25 March
2020), for which the Implicated In field included the term Prostate Cancer, and
were found within region 19,962,013–27,489,421 on 8p according to UCSC Gen-
ome Browser55 (http://genome.ucsc.edu/, accessed 25 March 2020), with GRCh38
assembly.
Chronological timing. Mutational signature 125 is known to represent a clock-like
process as it is generated at relatively constant rate56. We used WGS SNV calls
derived from fresh frozen samples from Gundem et al.11 to identify sets of point
mutations that corresponded to the trunk until the first intra-prostatic branch,
between the first branch and the first metastatic seeding event, and then from
seeding until sampling occurred. The non-negative matrix factorization method
used to identify mutational signatures is susceptible to errors when mutational
counts are low, as may be the case in some of our tree segments. As signature 1
consists of C > T mutations in a CpG context, we circumvented this issue by using
raw counts of these mutational types as a proxy for signature 1. These were gen-
erated based on the DPClust output where each single nucleotide variant from a
patient was assigned to a subclone. For each variant in each subclone, the Bio-
strings (version 2.48.0) and BSgenome (1.48.0) Bioconductor packages in R (ver-
sion 3.5.1) were used to retrieve the 5’ and 3’ adjacent bases of the mutation based
on the mutation coordinate. A count was kept of C > T mutations in a CpG context
on either the forward or reverse strand.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw targeted sequencing data have been deposited in the European Genome Archive
repository under the accession codes EGAD00001005381 and EGAD00001005382
(TenMenDeep EGA Datasets A and B respectively). The whole genome sequence data
referenced in this study are available from the European Genome Archive repository
under accession code EGAD00001000891 and is available on request. The gene name
data referenced during the study are available in a public repository from the UCSC
Genome Browser website (chromosome 8, GRCh38) [https://genome.ucsc.edu]. All the
other data supporting the findings of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary
Information file.
Code availability
Battenberg algorithm is available at https://github.com/cancerit/cgpBattenbergDPClust is
available at https://github.com/Wedge-Oxford/dpclust
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